Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Study suggests mGlyR could be a promising antidepressant target

By Brian Buntz | March 30, 2023

glycine and GPR158 Thibault Laboute copy 2

A model illustrates glycine molecules (teal) interacting with GPR158 brain cell receptors, influencing the nervous system. [Martemyanov lab, The Wertheim UF Scripps Institute]

A study published in Science has revealed important information about a brain receptor known as  mGlyR, which could be a potential antidepressant target. An abbreviation of “metabotropic glycine receptor,” mGlyR is highly active in the brain’s medial prefrontal cortex (mPFC). Abnormal activity in the brain region is associated with depression.

Formerly known as GPR158, mGlyR is a specific brain receptor type that responds to certain chemical signals. In addition to depression, researchers have linked mGlyr to cancer development and cognition. GPR158 directly interacts with a chemical known as glycine, which plays a role in various brain functions.

Both glycine and aurine affect mGlyR. Researchers believe these chemicals play a role in depression. “We have previously published research implicating GPR158 in the pathology of mood disorders,” said Kirill Martemyanov, professor and chair of the department of neuroscience at Scripps Biomedical Research. “Specifically, we found it to be upregulated in humans suffering from major depressive disorder and in mice subjected to stress, which is a major aggravating factor for depression.”

A 1995 study in European Neuropsychopharmacology found that glycine and taurine and other excitatory amino acids are dysregulated in the plasma of humans diagnosed with major depressive disorder. Additionally, a 2017 paper in Nature found that taurine has an antidepressant effect on stress-induced depressive rats.

“We also found that in mice, suppressing GPR158 leads to an antidepressant phenotype and resilience to stress,” Martemyanov said. “Therefore, we think that interventions aimed at blocking GPR158 would offer relief from stress-induced depression.”

mGlyR as a potential new antidepressant target

Kirill Martemyanov

Kirill Martemyanov

The recent study in Science found that glycine, but not taurine, works through mGlyR to regulate the activity of nerve cells in the brain’s cortex. This new information could help researchers better understand how brain connections work. The authors of the study believe that “using mGlyR for glycinergic signaling has implications for understanding mood disorders and for developing new treatment strategies.”

“We now know a new molecular system that regulates mood and gets dysregulated in affective disorders,” Dr. Martemyanov said. “We also have a target for developing medications — molecules with antagonistic activity for GPR158. Once they are developed, we can initiate clinical trials to see if our predictions in mice would bear out in humans and provide fast depression relief.”

The widespread presence of glycine and taurine, and their involvement in numerous bodily processes, limit their potential as medications. The authors note, however, that the identification of mGlyR offers a novel antidepressant target for developing new medications. The authors suspect that such novel drugs would be small molecules that specifically inhibit the mGlyR receptor, as they could prevent potential interactions with related receptors such as GPR179 found in the eye.

Implications for future depression therapies

This discovery highlights the potential for novel pharmacological strategies to address mood disorders by targeting the mGlyR receptor as an antidepressant target. Further research could lead to the development of more effective and targeted treatments for depression and other mood disorders.

Martemyanov highlighted the need for further research to better understand the balance of mGlyR receptors in the body and their effect on brain cell activity. “Glycine effects are non-specific — it engages a range of targets and is also a building block of proteins, hence metabolized easily,” he said. “We need specific small molecule drugs targeting GPR158. We also need to understand where exactly mGlyR is engaged and how it is regulated in the brain to produce effects on mood. This is the research we will be carrying out going forward.”


Filed Under: Drug Discovery, Psychiatric/psychotropic drugs
Tagged With: antidepressant target, brain receptors, depression treatment, glycine signaling, mGlyR receptor, mood disorders, new antidepressants, taurine
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Muse Clinic: Innovating with Psychedelics and Neurotechnology
Can LSD break the 20-year drought in anxiety treatment?
MAPS
FDA rejection of MDMA and journal retractions jolt psychedelic therapy research
MDMA
Experts endorse MDMA-assisted therapy for PTSD amid FDA adcomm setback
depression sadness and loneliness concept art illustration of wo
Precision psychiatry: A data-driven approach to personalized depression treatment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE